News
A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...
In a recent panel conversation, healthcare and industry experts discussed where to find reliable guidance in a sea of ...
Hims & Hers will begin offering generic semaglutide drugs in Canada next year after Novo Nordisk lost its exclusive patent ...
Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...
16h
Money Talks News on MSNAre Your Weight-Loss Drugs Real? Novo Nordisk Sounds Alarm on KnockoffsOne in eight Americans use GLP-1 weight-loss drugs, but are they getting the real thing? Novo Nordisk's dramatic exit from a popular platform reveals the hidden risks of online prescriptions.
18h
Zacks Investment Research on MSNCan Mounjaro and Zepbound Drive Another Strong Quarter for Eli Lilly?Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...
TOKYO-Nintendo's new Switch 2 videogame machine uses a rare-earth magnet to attach its hand-held controllers to the main console, according to a teardown, highlighting the company's vulnerability to ...
The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.
The state law gives Gov. Lamont "an enormous amount of negotiating leverage with the industry," Sen. Lesser said.
Novo Nordisk A/S (NYSE:NVO) is one of the 10 Best Growth Stocks to Buy With Huge Upside Potential. On June 23, Novo Nordisk A ...
This article summarizes recent health news, covering a spectrum of global issues. Highlights include Brazil's avian flu trade ...
Novo Nordisk's beaten-down valuation became too attractive to pass up, so I bought the stock earlier this year. Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results